BTK inhibitors
Oncology· 4 reviewed drugs· 13046 cited findings behind them
What the regulatory reviews cover
This library includes regulatory review documents for the BTK inhibitors Brukinsa, Imbruvica, Calquence, and Jaypirca. These drugs have been reviewed for indications such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström’s macroglobulinemia (WM), and chronic graft versus host disease (cGVHD).
Brukinsa's review for WM Cohort 1 reported Pyrexia (all grades) at 16%, compared to Ibrutinib at 13%. Imbruvica's review for CLL Study 2 noted a median duration of IMBRUVICA exposure of 8.6 months, versus 5.3 months for ofatumumab. Calquence's review for del 17p/TP53-mutated disease showed an ORR for Acala+Obin of 83-84, with the control arm at 56. Jaypirca's review for relapsed or refractory CLL reported an Overall Response Rate (ORR) by IRC (Phase 2 Only) of 51.8. It is important to note that these drugs were studied in different trials, and therefore, the figures are not directly comparable.
The drugs — one cited result each
| Brukinsa BeOne Medicines Ltd. | Pyrexia (all grades, WM Cohort 1, BRUKINSA): 16 BeOne Medicines Ltd. — Brukinsa FDA Review (NDA/BLA 213217,, p.21 |
| Imbruvica AbbVie Inc. | Median duration of IMBRUVICA exposure in CLL Study 2: 8.6 months PHARMACYCLICS LLC — Imbruvica FDA Review (NDA/BLA 205552, 20, p.19 |
| Calquence AstraZeneca PLC | ORR for Acala+Obin in del 17p/TP53-mutated disease: 83-84 AstraZeneca PLC — Calquence EMA EPAR public assessment repor, p.144 |
| Jaypirca Eli Lilly and Company | Overall Response Rate (ORR) by IRC (Phase 2 Only): 51.8 Eli Lilly and Company — Jaypirca EMA EPAR public assessment, p.92 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Oncology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.